NCT06633276 Fast and Accurate Breast Cancer Diagnosis Using Nanopore Sequencing in Tanzania (Fast-ABCD Sequencing)
| NCT ID | NCT06633276 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Bonn |
| Condition | Breast Cancer Invasive |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-05 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-05 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot study will test the feasibility of using nanopore sequencing for breast cancer diagnosis in Tanzania. It aims to show that nanopore sequencing is non-inferior to the current standard of care, with the potential for faster and more cost-efficient results. By enhancing the speed and accuracy of diagnosis, this approach could improve treatment planning and outcomes for patients in resource-limited settings.
Eligibility Criteria
Inclusion Criteria: * Patient with suspected diagnosis of breast cancer undergoing biopsy or surgical resection after specialist consultation as per institutional guidelines * Excess fresh tumor sample * Written informed consent Exclusion Criteria: * Unable to provide informed consent * Patients who have already commenced therapy for BC (except for treatment other than biomedicine, e.g. herbal medicines)
Contact & Investigator
Oliver Henke, MD
PRINCIPAL INVESTIGATOR
Section Global Health, University Hospital Bonn
Frequently Asked Questions
Who can join the NCT06633276 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer Invasive. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06633276 currently recruiting?
Yes, NCT06633276 is actively recruiting participants. Contact the research team at Oliver.Henke@ukbonn.de for enrollment information.
Where is the NCT06633276 trial being conducted?
This trial is being conducted at Moshi, Tanzania.
Who is sponsoring the NCT06633276 clinical trial?
NCT06633276 is sponsored by University of Bonn. The principal investigator is Oliver Henke, MD at Section Global Health, University Hospital Bonn. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.